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Abstract
Multiple sclerosis (MS) is a chronic and debilitating neurological disorder of the central nervous system (CNS),
characterized by infiltration of leukocytes into CNS and subsequent demyelination. Emerging evidences have revealed
the beneficial roles of M2 macrophages in ameliorating experimental autoimmune encephalomyelitis (EAE), a model
for MS. Here, we identify that lenalidomide alone could promote macrophages M2 polarization to prevent the
progression of EAE, which is associated with subsequent inhibition of proinflammatory Th1 and Th17 cells both in
peripheral lymph system and CNS. Depletion of macrophages by pharmacology treatment of clodronate liposomes or
transferring lenalidomide-induced BMDMs in EAE mice completely abolished the therapeutic effect of lenalidomide or
prevented EAE development, respectively. The macrophages-derived IL10 was upregulated both in vivo and in vitro
after lenalidomide treatment. Moreover, lenalidomide-treated IL10-dificient EAE mice had higher clinical scores and
more severe CNS damage, and intravenous injection of lenalidomide-treated IL10−/− BMDMs into mice with EAE at
disease onset did not reverse disease severity, implying IL10 may be essential in lenalidomide-ameliorated EAE.
Mechanistically, lenalidomide significantly increased expression and autocrine secretion of IL10, subsequently
activated STAT3-mediated expression of Ym1. These studies facilitate the development of potential novel therapeutic
application of lenalidomide for the treatment of MS.
Introduction
Multiple sclerosis (MS) is an autoimmune inflammatory
demyelinating disease, pathologically characterized by
perivascular CD4+ T cells and monocytes inflammation,
resulting in axonal demyelination and transection1–3.
Current therapy of MS such as fingolimod, glatiramer
acetate mainly depends on non-specific suppression of the
immune system to delay the progression4 and reduce the
frequency and severity of disease relapse periods. How-
ever, they cannot protect myelin from future damage5,6.
Thus, more effective pharmacological strategies for MS to
reduce inflammation and diminish myelin damage in
injured CNS is urgently needed.
In recent years, it has become clear that macrophages
play a very important role in the pathogenesis of MS7. The
function of macrophages in experimental autoimmune
encephalomyelitis (EAE), a widely used animal model of
MS8, is often opposite9. M1 cells are classically activated
macrophages, generally exhibit proinflammatory activity,
whereas M2 cells are alternatively activated macrophages,
predominantly inhibit immune responses10. M1 and M2
macrophages co-exist in vivo and present plastic
© The Author(s) 2018
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Bo Yang (yang924@zju.edu.cn) or Qiaojun He
(qiaojunhe@zju.edu.cn)
1Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of
Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang
University, Hangzhou, China
2Center for Drug Safety Evaluation and Research, Zhejiang University,
Hangzhou, China
Full list of author information is available at the end of the article
These authors contributed equally: Qinjie Weng, Jiaying Wang, Jiajia Wang.
Edited by T Brunner
Official journal of the Cell Death Differentiation Association
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
properties regulated by members of the STAT family in
the peripheral lymph system and CNS during the disease
progress. STAT1/NF-κB axis promotes IFNs and Toll-like
receptor (TLR) to skew macrophage function toward the
M1 phenotype, whereas STAT3/STAT6 signaling path-
way activated by IL4, IL10, or IL13 induces M2 macro-
phages phenotype11. The distribution of M1 macrophages
in CNS lesion causes oligodendrocyte precursor cells
death12 while M2 macrophages induce pro-repair mole-
cules such as brain-derived neurotropic factor (BDNF),
IL10, and ferritin increasing the maturation of oligoden-
drocyte precursor cells13,14. Moreover, M2 macrophages
remove inhibitory debris or toxic products enabling sub-
sequent remyelination15. Macrophages interactions with
CD4+ T cells in demyelinating lesions have been sug-
gested to play a critical role in modifying the pathobiology
of MS16. As professional antigen-presenting cells (APCs),
M1 macrophages prime naive CD4+ T cells and initiate
auto-reactive immune response in CNS17, releasing many
inflammatory mediators such as interleukin-1 (IL-1)18,
tumor necrosis factor-alpha (TNF-α)19, and NO20, that
are critical for EAE development21. However, M2 mac-
rophages suppress CD4+ T cells activity in demyelinated
CNS. Indeed, transferring of microglia- or monocyte-
derived M2 macrophages could reduce the severity of
clinical signs of EAE by inhibiting T cell proliferation22.
The transition from M1 to M2 macrophages has been
reported to be crucial for preserving myelin integrity12.
Thus, the modulations of molecules associated with
macrophage plasticity and polarized activation are critical
to modulate CNS inflammation and tissue repair.
Here, we identified that lenalidomide, an oral drug
approved by FDA for the treatment of myelodysplastic
syndromes and multiple myeloma23,24, markedly pro-
moted the M2 polarization of macrophages alone thus
mediated immunosuppressive and neuroprotective effect
in EAE. Moreover, lenalidomide induced M2 macro-
phages polarization mainly through expression and
autocrine secretion of IL10 and subsequent activation of
STAT3.
Fig. 1 Lenalidomide promotes M2 macrophages polarization. a, b qRT-PCR analysis for expression of macrophage M2 phenotype genes in
RAW264.7 (a) and BMDMs (b) with lenalidomide treatment for 4 h, IL13 (10 ng/ml) was used as positive control (n = 3). c, d Western blotting analysis
for expression of Arg1 and Ym1 in RAW264.7 (c) and BMDMs (d) with lenalidomide treatment for 4 h. GAPDH or β-actin was the loading control (n =
3). e Flow cytometry analysis of the percentage of M2 phenotype (CD206+ cells) in RAW264.7 cells with lenalidomide (25 nM) treatment for 4 h. IL13
(10 ng/ml) was used as positive control (n = 3). f Flow cytometry analysis of the percentage of M2 phenotype (CD206+F4/80+ cells) in BMDMs with
lenalidomide (25 nM) treatment for 4 h (n = 3). Cells were gated at F4/80+ cells. g, h BMDMs were pretreated with LPS (50 ng/ml) for 24 h and then
administrated with lenalidomide (25 nM) for additional 4 h. qRT-PCR was carried out to analyze mRNA level of macrophage M1 phenotype genes (n
= 3) (g). Flow cytometry analysis was carried out to characterize the percentage of M1 phenotype (CD86+F4/80+ cells), cells were gated at F4/80+ cells
(n = 3) (h). Data are presented as means ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001 versus untreated control
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Results
Lenalidomide alone directly induces M2 phenotype in
macrophages
Recent studies have revealed that the balance between
activation and polarization of M1 and M2 macrophages is
important for the progression of EAE. Polarized macro-
phages can be modulated by pharmacological interven-
tion. Therefore, we employed qRT-PCR experiment
screening a variety of compounds/drugs, including anti-
metabolites (pemetrexed and gemcitabine), anti-
histamine drugs (loratadine and promethazine), 5-HT
receptor antagonists (azasetron and palonosetron),
immunomodulators (lenalidomide and pomalidomide),
and novel compounds (referred to as C1–C2) in bone
marrow-derived macrophages (BMDMs) in order to find a
compound/drug, which selectively induces M2 phenotype
or inhibits M1 phenotype. We found that the upregula-
tion of Arg1 and Mrc1 mRNA level induced by lenalido-
mide, about 27.3 and 6.7 times, is closer to that induced
by IL13, while pomalidomide upregulated the mRNA level
of Arg1 and Mrc1 only by 18.6 and 3.9 times, respectively
(Supplementary Figure S1a, b). Those compounds/drugs
could not markedly inhibit the mRNA level of Inos and
Cxcl10 induced by LPS stimulation (Supplementary
Fig. 2 Lenalidomide ameliorates EAE progression. a, b Wild-type (WT) mice were immunized with MOG35–55 peptide and treated with
lenalidomide (30 mg/kg, i.g.), dexamethasone (10 mg/kg, i.g.), or vehicle (0.9% CMC-Na, i.g.) at indicated time points (arrows). Mean clinical score (a)
and loss of body weight (b) are shown (n = 15 per group). c H&E and Luxolfast blue (LFB) staining of mouse spinal cords from vehicle- and
lenalidomide-treated WT EAE mice at day 16. Arrowheads indicate leukocyte infiltration area in H&E staining. Outlines indicate demyelination in LFB
staining. Scale bars: 100 μm. d Immunostaining of mouse spinal cords from vehicle- and lenalidomide-treated WT EAE mice at day 16 using
antibodies against Olig2 (red) and CC1 (green). Scale bars: 50 μm. e Quantification of Olig2+ cells density in spinal cords in d. f Quantification of the
percentage of Olig2+CC1+ cells among Olig2+ cells from spinal cords in d. g Representative electron micrographs of spinal cords from vehicle- and
lenalidomide-treated WT EAE mice at day 16. Scale bars: 2 μm. h g-ratios of axons in spinal cords from vehicle- and lenalidomide-treated WT EAE
mice at day 16 (n > 100). Data are presented as means ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001 versus vehicle-treated controls
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Figure S1c, d). The further qRT-PCR analysis demon-
strated lenalidomide significantly increased the mRNA
level of M2 macrophages-related genes of Ym1, Arg1 and
Mrc1 in RAW264.7 (monocyte-derived macrophage cell
line), as well as in BMDMs (Fig. 1a, b and Supplementary
Figure S2a). And western blotting analysis showed that
lenalidomide enhanced the expression of Arg1 and Ym1
in macrophages (Fig. 1c, d). Moreover, flow cytometry
analysis indicated that lenalidomide treatment sig-
nificantly increased CD206+ M2 cells (Fig. 1e, f). Never-
theless, lenalidomide did not inhibit LPS-induced M1
polarization in BMDMs (Fig. 1g, h and Supplementary
Figure S2b). Taken together, our results clearly demon-
strate that lenalidomide alone could obviously increase
M2 macrophages polarization.
Lenalidomide ameliorates EAE symptom and reduces
demyelination
Given that M2 macrophages have effect on inflamma-
tion resolution and tissue repair in EAE25, we tested
whether lenalidomide might be able to ameliorate the
development of autoimmune diseases. Therefore, C57BL/
Fig. 3 Lenalidomide suppresses autoimmune responses in EAE. a, b Flow cytometry analysis of Th1 and Th17 cells in spleen (a) and DLN (b)
from vehicle- and lenalidomide-treated WT EAE mice at day 17. Representative fluorescence activated cell sorting (FACS) plots (left) and statistics
from six mice per group (right) are shown; cells are gated for CD4+ T cells. c The total numbers of MNCs in whole spinal cord and brain were isolated
from vehicle- and lenalidomide-treated mice on day 17 (n = 6). d Flow cytometry analysis of Th1 and Th17 cells in CNS-infiltrating MNCs from vehicle-
and lenalidomide-treated WT EAE mice at day 17. Representative FACS plots (left) and statistics from six mice per group (right) are shown; cells are
gated for CD4+ T cells. Data are presented as means ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001 versus vehicle-treated controls
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6 mice were immunized with MOG35–55 peptide and
treated daily with lenalidomide after onset of clinical
symptoms. Expectedly, lenalidomide ameliorated the
disease severity from the early stage and lasted until the
end of experiment, whereas vehicle-treated mice showed
continued disease progression (Fig. 2a, b). Moreover,
inflammatory foci areas in spinal cord of lenalidomide-
treated mice were reduced compared with vehicle-treated
mice (Fig. 2c, left). The inflammatory cells will attack the
myelin to cause demyelination26, we next detect the
myelin-forming cells and myelin integrity. Immuno-
fluorescence analysis showed that the number of Olig2+
cells and Olig2+CC1+ cells in the spinal cords white
matter of lenalidomide-treated mice compared with EAE
Fig. 4 The protective effect of lenalidomide on EAE is dependent on M2 phenotype. a WT mice were immunized with MOG35–55 and treated
with lenalidomide (30 mg/kg, i.g.) or vehicle (0.9% CMC-Na, i.g.) combined with empty or clodronate liposome (50mg/kg, i.v.) at indicated time
points (bottom arrows represent lenalidomide or vehicle treatment, upper arrows represent liposome treatment). Mean clinical score is shown (n = 15
per group). b, c Flow cytometry analysis of M2 and M1 macrophages in spleen (b) and DLN (c) from vehicle- and lenalidomide-treated WT EAE mice
at day 17. Representative FACS plots (left) and statistics from six mice per group (right) are shown; cells are gated for F4/80+ cells. d Flow cytometry
analysis of M2 macrophages in whole spinal cord and brain. CNS-infiltrating MNCs isolated from vehicle- and lenalidomide-treated WT EAE mice at
day 17 stained for antibodies, including CD11b, CD206, and CD45. CD11b+CD45hiCD206+ cells were M2 macrophages. Representative FACS plots
(left) and statistics from six mice per group (right) are shown. e WT mice were immunized with MOG35–55 on day 0 and 3 × 10
6 BMDMs treated with
or without 25 nM lenalidomide for 4 h were injected intravenously into these mice on day 9, 14, and 19 (n = 5 per group). f The mean clinical score of
mice in e. g BMDMs were treated with or without 25 nM lenalidomide for 4 h. Splenic CD4+ T cells were isolated from MOG-treated WT mice, labeled
with1 μM CFSE and subsequently cocultured with BMDMs at a ratio of 1:4 supplemented with MOG35–55 peptide (20 μg/ml) for 72 h. The proliferation
of CD4+ T cells was confirmed by flow cytometry analysis based on CFSE dilution. Left panel represents flowcytometric dot plot of CFSE-labeled CD4+
T cells, right panel shows the percentage of CD4+ T cells that have proliferated based on CFSE dilution (n = 3 per group). Data are presented as
means ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001
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control mice were significantly increased (Fig. 2d–f).
Consistently, LFB analysis also indicated a decreased
demyelination in the spinal cord of lenalidomide reci-
pients in contrast to vehicle-treated EAE mice (Fig. 2c,
right). Moreover, vehicle-treated EAE mice showed
extensive demyelination compared to lenalidomide-
treated EAE mice, with unraveling of the myelin sheaths
and loss of axon (Fig. 2g). g-ratios (the ratio between the
diameter of the axon to myelinated axon diameter) was
used to quantify myelin thickness. Lenalidomide markedly
decreased the g-ratios from 0.82 to 0.73 (Fig. 2h). These
results indicate that lenalidomide could alleviate the
symptoms of EAE mainly through decreased inflamma-
tory cells infiltration in CNS and strong attenuating
typical demyelination.
Lenalidomide suppresses proinflammatory Th1 and Th17
cells responses
T cells and B cells contribute to autoimmune CNS
inflammation and demyelination27, we therefore per-
formed flow cytometry analysis to evaluated possible
regulatory immune responses by lenalidomide in vivo.
The experiments data demonstrated that lenalidomide
treatment dramatically reduced IFN-γ+ and IL17+ CD4+
T cells in draining lymph node (DLN) and spleen (Fig. 3a,
b), but had no effect on Foxp3+CD4+ T and B220+ B cells
(Supplementary Figure S3a–d), suggesting that lenalido-
mide injection inhibited pathogenic Th1 and Th17 cells
activity in vivo. To verify the modulated effect of lenali-
domide on immune cells infiltration into CNS, we sepa-
rated and quantified mononuclear cells (MNCs) from the
whole spinal cord and brain at the peak phase of disease.
In contrast to vehicle-treated EAE mice, the number of
CNS-infiltrating MNCs in lenalidomide-treated EAE mice
were reduced by 2.5 times (Fig. 3c). Similarly, flow cyto-
metry analysis observed that Th1 and Th17 cells pene-
trated into CNS were threefold reduction in lenalidomide-
injected mice (Fig. 3d). Taken together, we speculate that
lenalidomide inhibits effector T cells polarization in
spleen and DLN, which induces the reduction of inflam-
matory Th1 and Th17 cells penetrating into the CNS.
Lenalidomide-attenuated EAE is dependent on polarized
M2 macrophages
To analyze whether macrophages related to the bene-
ficial effect of lenalidomide in EAE, macrophages in
spleen and spinal cord were selectively depleted using the
“suicide technique” by application of clodronate liposomes
(c-lipo). After administrating c-lipo, EAE mice could not
be protected from disease progression upon lenalidomide
treatment, particularly obvious at day 15 post immuni-
zation, clearly indicating that lenalidomide ameliorates
CNS autoimmunity depending on the effect of macro-
phages (Fig. 4a). This hypothesis was further strengthened
by the observation of macrophages subtypes in EAE mice.
Reduction of disease severity in lenalidomide-treated mice
was in paralleled with increased numbers of F4/
80+CD206+ M2 cells both in spleen and DLN compared
to vehicle-treated mice, however, the percentage of F4/
80+CD86+ M1 cells remained unchanged (Fig. 4b, c). In
addition, the frequency of activated
CD11b+CD45hiCD206+ M2 macrophages in spinal cords
was increased from 3.94 to 8.36% after treatment with
lenalidomide (Fig. 4d). Based on our findings so far, we
next transferred lenalidomide-pretreated BMDMs (Sup-
plementary Figure S4a, b) into EAE mice every 5 days
from the day of the appearance of clinical symptoms
(Fig. 4e). After injection, adoptive transferred mice with
M2 macrophages had lower clinical scores (Fig. 4f). The
previous data showed that lenalidomide had effect on
both CD4+ T cells and M2 macrophages in EAE mice, it is
still unsure whether lenalidomide directly affects the
function of myelin-specific CD4+ T cells or indirectly by
regulating the function of macrophages. Indeed, we
observed that CD4+ T cells were insensitivity to lenali-
domide at a concentration of M2 cells polarization.
However, higher concentration of lenalidomide (2 μM)
augmented IFN-γ+CD4+ T cells (Supplementary Fig-
ure S5a, b), which is consistent with the previous stu-
dies28. Moreover, MOG-induced reaction of CD4+ T cells
in vitro was not inhibited by lenalidomide (Supplementary
Figure S5c), indicating that the therapeutic effect of
lenalidomide on EAE mice was dependent on M2 mac-
rophages polarization rather than direct inhibition of
CD4+ T cells. Thus, we addressed whether lenalidomide-
induced M2 macrophages have the capacity to inhibit
myelin-specific CD4+ T cells, the result showed that
MOG peptide-induced proliferation of CD4+ T cells was
significantly inhibited when presented macrophages sti-
mulated with lenalidomide (Fig. 4g). These results
demonstrate that lenalidomide indirectly altering the
proinflammatory activity of myelin-specific CD4+ T cells
mainly through promoting the polarization of M2
macrophages.
Macrophages-derived IL10 is essential for the therapeutic
effect of lenalidomide on EAE
M2 macrophages secrete anti-inflammation cytokines
including IL4, IL10, IL13, and TGF-β10. Based on this, we
then tested whether lenalidomide was able to upregulate
these factors. Expectedly, BMDMs stimulated with lena-
lidomide, confirmed by qRT-PCR analysis, led to a sig-
nificant increase of Il4, Il10, Il13, and Tgf-β mRNA level,
especially, Il10 mRNA increased about 25 times (Fig. 5a).
Consistently, lenalidomide markedly increased IL10 pro-
duction in serum, spleen, and spinal cord from EAE mice
harvested at day 17 (Fig. 5b, c). IL10 can be produced in
response to proinflammatory signals by virtually all
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immune cells, including T cells, B cells, and macro-
phages29–31. We conducted IHC and flow cytometry
analysis to validate the source of IL10 in the presence of
lenalidomide, the data revealed that the majority of IL10+
cells are also CD68+ macrophages (Fig. 5d–g), but not
CD4+ T cells or CD8+ T cells (Supplementary
Figure S6a–d), suggesting that IL10 was mainly produced
by M2 macrophages. We next detected IL10’s role in
lenalidomide-induced macrophages M2 polarization. In
contrast to higher protein levels of Ym1 in IL10-sufficient
BMDMs induced by lenalidomide, IL10-deficient
BMDMs showed remarkably decreased Ym1 protein
(Fig. 5h). To clearly distinguish whether the protective
effect of lenalidomide was indeed mediated by IL10
in vivo, WT and IL10-deficient (IL10−/−) mice were
immunized and treated with lenalidomide. Expectedly,
IL10−/− EAE mice treated with lenalidomide had higher
mean clinical scores and more severe demyelination
compared to lenalidomide-treated WT mice (Fig. 5i, j).
Then, we used adoptive transfer experiment injecting
Fig. 5 IL10-producing M2 macrophages play a critical role in lenalidomide treatment. a qRT-PCR analysis for expression of Il4, Il10, Il13, and Tgf-
β in WT BMDMs with 25 nM lenalidomide treatment for 4 h (n = 3). b Concentration of IL10 in serum from vehicle or lenalidomide-treated WT EAE
mice at day 17 (n = 6). c Concentration of IL10 in spleen and spinal cord from vehicle- or lenalidomide-treated WT EAE mice at day 17 (n = 6). d
Immunostaining of mouse spinal cords from vehicle- and lenalidomide-treated WT EAE mice at day 16 using antibodies against CD68 (green) and
IL10 (red). Scale bars: 150 μm (left), 50 μm (right). e Quantification of the percentage of CD68+ IL10+ cells among CD68+ cells from spinal cords in d. f,
g Flow cytometry analysis of IL10+CD206+ cells in spleen and DLN from vehicle or lenalidomide-treated WT EAE mice at day 17. Representative FACS
plots (f) and statistics from six mice per group (g) are shown. Cells are gated for CD206+ cells. hWestern blotting analysis for expression of Ym1 in WT
or IL10−/− BMDMs with 25 nM lenalidomide treatment for 4 h. GAPDH was the loading control. i WT or IL10−/− mice were immunized with MOG35–55
and treated with lenalidomide (30 mg/kg, i.g.) or vehicle (0.9% CMC-Na, i.g.) at indicated time points (arrows). Mean clinical score is shown (n = 15 per
group). j MBP and LFB staining of spinal cord from lenalidomide-treated WT or IL10−/− EAE mice in i at day 15. Scale bars: 200 μm (upper), 100 μm
(bottom). k WT mice were immunized with MOG35–55 on day 0 and 3 × 10
6 WT or IL10−/− BMDMs treated with or without 25 nM lenalidomide for 4 h
were injected intravenously into these mice at day 12. Mean clinical scores are shown (n = 8 per group). Data are presented as means ± SEM; *P <
0.05, **P < 0.01, ***P < 0.001
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lenalidomide-treated WT or IL10−/− BMDMs to EAE
mice on day 12. Consistent with in vivo data, IL10−/−
BMDMs were not able to inhibit the process of disease,
while WT-BMDMs transferred mice displayed lower
clinical scores (Fig. 5k). These results confirm that
lenalidomide-ameliorated EAE is, at least partially,
dependent on IL10-producing M2 macrophages.
Lenalidomide promotes M2 macrophages polarization via
IL10-STAT3-IL10 positive feedback loop
Subsequently, we investigated how lenalidomide reg-
ulates M2 macrophages polarization. It has been reported
that activated STAT6, as well as AKT and STAT3 can
shift macrophages from the destructive M1 phenotype
toward the beneficial M2 phenotype11,32. The western
blotting analysis was performed in lenalidomide-treated
RAW264.7 and BMDMs. The data showed that lenali-
domide did not activate AKT and STAT6 in RAW264.7.
However, lenalidomide upregulated STAT3 phosphor-
ylation in a concentration-dependent fashion in both
RAW264.7 cells and BMDMs (Fig. 6a). Moreover, IL10
protein level was upregulated then subsequently activated
STAT3 in macrophages after lenalidomide treatment
(Fig. 6b). We also detected that IL10 cytokine secretion
began to increase after 4 h lenalidomide treatment
(Fig. 6c). Moreover, pretreatment with recombinant anti-
IL10 mAb suppressed Tyr-705 phosphorylation-mediated
Ym1 expression. In addition, pretreatment with STAT3
inhibitor Cucurbitacin (CuCu) could partially reverse
lenalidomide-stimulated macrophages M2 polarization
(Fig. 6d, e). In vivo study confirmed that lenalidomide
obviously increased Arg1+ p-STAT3+ cells in spleen of
EAE mice (Fig. 6f). Accordingly, lenalidomide significantly
increases expression and autocrine secretion of IL10,
subsequently activates STAT3-mediated expression of
Ym1.
Discussion
Here, we demonstrated that lenalidomide efficiently
inhibited prototypical inflammatory demyelinating disease
of CNS. Lenalidomide alone significantly activated M2
macrophages and inhibited proinflammatory Th1 and
Th17 cells both in the peripheral lymph system and CNS,
thus resulting in reduced inflammation and demyelination
in injured CNS tissues. At the cellular level, lenalidomide
efficiently promoted the expression and autocrine of IL10,
subsequently phosphorylated STAT3 Tyr-705, and finally
led to the induction of M2 macrophages (Fig. 7).
It has been reported that lenalidomide administration is
neuroprotective in a mouse model of amyotrophic lateral
sclerosis at symptom onset stage33,34, as well as in a
transgenic model of Parkinson’s disease35 by decreasing
the expression of the proinflammatory cytokines. Here,
we found that administration of lenalidomide by gavage
prevented EAE from the early stage and lasted until the
end of experiment by reducing inflammation and
demyelination. However, this observation was incon-
sistent with previous studies. The paper indicated that
intraperitoneal administration of lenalidomide delayed
symptom onset of EAE, but did not prevent demyelina-
tion36. We speculated that lenalidomide could not be fully
dissolved in 1% carboxymethyl cellulose and 0.9% saline
solution according to our formulation preparation (data
not shown), lenalidomide by intraperitoneal administra-
tion was unable to fully absorbed in the abdominal cavity.
Furthermore, the doses of lenalidomide was lower than
we used in this paper.
Although many cytokines, including IL4, IL13, and
IL10, efficiently direct M2 macrophages polarization10,
they are not suitable for clinical use37. The previous trials
that treated EAE mice with systemic IL10 did not show
any promising effect and was found, at least in some
studies, to aggravate disease38. A small quantity of com-
pounds, such as pidotimod and azithromycin, could
induce the polarization of M2 macrophages in an IL4- or
IL13-depedent manner39,40; however, azithromycin had
no therapeutic effect on EAE mice41. Here, we found that
lenalidomide alone obviously induced M2 phenotype and
did not affect M1 phenotype both in RAW264.7 and
primary macrophages, however, whether lenalidomide
modulates M2 macrophages polarization in human mac-
rophages still need to be studied. Moreover, we observed
that depletion of macrophages with c-lipo completely
abolished the beneficial effects of lenalidomide on EAE
while adoptive transferring of lenalidomide-induced
macrophages ameliorated EAE, demonstrating that
lenalidomide-alleviated inflammation and demyelination
is mainly through promoting M2 macrophages polariza-
tion. Macrophages and CD4+ T cells both play important
roles in the neuropathology of MS, and the interactions
between CD4+ T helper cell subsets and M1 and M2
macrophages often result in particular functions and
outcomes16. Autoreactive CD4+ T cells from peripherally
infiltrate into the CNS, where they are restimulated by M1
macrophages, leading to local expansion of pathogenic
Th1 and Th17 cells, and subsequently damage to oligo-
dendrocytes42. Indeed, injection of M2 macrophages into
mice with EAE has been shown to reduce the frequency
and severity of disease relapse periods by suppressing T
cell activity22,43. Exposing of T cells to lenalidomide leads
to increased IFN-γ and IL-2 secretion44, however, we
found that it did not directly inhibit MOG-loaded CD4+
T cells. Moreover, we here provided evidence that
lenalidomide-induced M2 macrophages diminished the
proliferation ability of MOG-specific CD4+ T cells
ex vivo.
IL10 is an anti-inflammatory cytokine and its primary
function is to limit inflammatory responses, which has
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been well studied in the pathogenesis of several auto-
immune diseases including EAE45. Lenalidomide could
reduce the survival support of NLCs for chronic lym-
phocytic leukemia (CLL) cells in vitro by increasing
secretion of IL1046. Consistently, we showed here that
lenalidomide promoted IL10 expression both in vivo and
ex vivo in macrophages. IL10 played important roles in
lenalidomide therapy as IL10−/− mice could not be pro-
tected from actively induced EAE upon lenalidomide
treatment. IL10 can be produced in response to proin-
flammatory signals by virtually all immune cells, including
T cells, B cells, and macrophages29–31. Plasmablasts in the
DLN serve as IL10 producers to limit autoimmune
inflammation47 and CD4+ T cells-induced IL10 was
associated with the beneficial effects of Bowman–Birk
inhibitor (BBI) on EAE48. Here, we show that the effect of
lenalidomide strictly depended on M2 macrophages-
secreted IL10, as adoptive transferring of lenalidomide-
activated IL10-sufficient macrophages improved EAE
progress, however, IL10−/− macrophages could not res-
cue EAE clinical scores. These findings emphasize the
importance of M2 macrophages as IL10 producer for
control of CNS autoimmunity. Up to now, the role of IL10
in macrophages has been clearly characterized and two
important signaling axes have been reported to be acti-
vated through IL10 receptor ligation in macrophages, the
JAK1/STAT3 and PI3K/Akt/GSK3β pathways49,50. We
found here that lenalidomide-induced M2 macrophages
Fig. 6 Lenalidomide-induced M2 macrophage polarization is dependent on STAT3. a Western blotting analysis for expression of STAT3, p-
STAT3(Y705), AKT, p-AKT(Y473), STAT6, and p-STAT6 (Y641) in RAW264.7 (upper panel) and BMDMs (lower panel) treated with lenalidomide in
different concentration for 4 h (n = 3). b Western blotting analysis for expression of IL10, p-STAT3 (Y705) in RAW264.7 (upper panel), and BMDMs
(lower panel) with 25 nM lenalidomide treatment for a gradient time (n = 3). c RAW264.7 (upper panel) and BMDMs (lower panel) were cultured in
serum-free medium and treated with lenalidomide for different times. Supernanant was cultured at indicated time to test the concentration of IL10
(n = 3). d RAW264.7 (upper panel) and BMDMs (lower panel) were cultured in serum-free medium, added anti-IL10 antibodies for 12 h and treated
with lenalidomide for an additional 4 h. Western blotting analysis for expression of p-STAT3 (Y705) and Ym1. e RAW264.7 (upper panel) and BMDMs
(lower panel) were pretreated with CuCu for 2 h and then treated with lenalidomide for an additional 4 h. Western blotting analysis for p-STAT3
(Y705) and Ym1. f Immunostaining of spleen from vehicle- and lenalidomide-treated EAE mice at day 16 using antibodies against p-STAT3 (Y705)
(red) and Arg1 (green). Scale bars: 150 μm. GAPDH and β-actin were the loading control
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depended on STAT3 activation. IL10/STAT3 axis is
successfully studied in M2 macrophages, IL10 binding to
IL10R51,52 activates the IL10/JAK1/STAT3 cascade, then
phosphorylates STAT3 homodimers translocate to the
nucleus within seconds to activate the expression of M2
macrophages-related genes53. STAT3 has pathological
implications for MS due to its critical roles in myeloid cell
activation, T cell polarization, and cytokine/chemokine
induction54,55. However, whether hyperactivation of
STAT3 in macrophages renders mice resistant to EAE
disease need to be further studied.
Here, we found that therapeutic administration of
lenalidomide significantly controls disease severity, and
improves behavior in mice with EAE, suggesting that
lenalidomide could be used for the treatment of
inflammation-associated degenerative CNS diseases, such
as relapsing-remitting MS. Lenalidomide is therefore a
promising therapeutic drug candidate for attenuating
inflammatory responses and reducing neuronal demyeli-
nation in CNS in MS.
Materials and methods
Animals and EAE mice induction
C57BL/6 mice, 6–8-week old, female, were purchased
from Beijing Vital River Laboratory Animal Technology
Co., Ltd. IL10−/− mice, 6–8-week old, female, were pur-
chased from Model Animal Research Center of Nanjing
University. Those mice were immunized subcutaneously
with 400 μg MOG35–55 peptide (Sangom Biotech) emulsi-
fied in CFA (Sigma) containing 4mg/ml heat-killed
Mycobacterium tuberculosis H37Ra (BD Biosciences) on
day 0. In addition, 200 ng pertussis toxin (List Biological
Laboratories) in 0.1ml PBS was administered intravenously
on day 0 and day 1 post immunization per mice. Animals
were assessed daily for weight loss and clinical signs with a
0–5 point scoring system as follows: 0, healthy; 0.5, tip of
tail is partial paralysis; 1, limp tail; 1.5, inhibition of hin-
dlimb; 2, weakness of hindlimb; 2.5 dragging of hindlimb; 3,
one hindlimb paralysis; 3.5, complete hindlimb paralysis; 4,
one forelimb paralysis; 4.5, complete forelimb paralysis; and
5, severe paralysis or death.
Cell culture
RAW264.7 cells were purchased from Cell Bank of
Chinese Academy of Sciences, cultured in DMEM
(GIBCO) containing 10% (vol/vol) FBS (GIBCO). BMDMs:
bone marrow cells were isolated from femurs and tibias of
C57BL/6 mice and cultured in DMEM containing 10%
(vol/vol) FBS and 50 ng/ml of M-CSF (PEPROTECH) for
7 days. Purity was determined by flow cytometry.
Drugs/compounds screening
Drug/compounds screening for promoting M2 macro-
phages polarization: BMDMs were seeded in 24-well plate
presented with 100 nM drugs/compounds for 24 h. IL13
(10 ng/ml, PEPROTECH) was used as positive control for
macrophages M2 polarization. Following qRT-PCR ana-
lysis for expression of Arg1 and Mrc1. Drug/compounds
screening for inhibiting macrophages M1 polarization:
BMDMs were seeded in 24-well plate presented with LPS
(50 ng/ml) for 24 h to induce M1 phenotype and then
treated with drugs/compounds (100 nM) for additional
24 h. Following qRT-PCR analysis for expression of Inos
and Cxcl10.
Fig. 7 Schematic representation of lenalidomide-mediated M2 polarization and neuroprotective effect. Lenalidomide is uptaken by
macrophages and directly promotes macrophages M2 polarization by IL10-STAT3 signaling pathway. Specifically, lenalidomide effectively increases
IL10 expression and subsequently phosphorylates STAT3 Tyr-705. Phosphorylated STAT3 translocated into the nucleus encoding M2 macrophages-
related genes such as Arg1, Ym1, and CD206. Anti-inflammatory cytokines secreted by M2 macrophages can reduce the infiltration of peripherally
generated autoreactive Th1 and Th17 cells into CNS, inhibit demyelination, and therefore prevent of EAE
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Compounds and pharmacological treatment
For RAW264.7 and BMDMs, lenalidomide was dis-
solved in DMSO at proper concentration. For EAE mice,
vehicle (0.9% CMC-Na, i.g.), dexamethasone (Tianjin
Kingyork Group Co., Ltd, 10 mg/kg, i.p.) and lenalidomide
(Chia Tai Tianqing Pharmaceutical Group Co., Ltd, 30
mg/kg in 0.9% CMC-Na, i.g.) were daily administrated
after the appearance of clinical symptom (average clinical
score ≥0.5). To selectively deplete macrophages, clo-
dronate liposome (Encapsula, 50 mg/kg, i.v.) was admi-
nistrated on day 7, 8, 11, 12, 15, and 16 after
immunization.
Suppression assays
BMDMs were generated as described above and on day
7 of differentiation, cells were treated with or without 25
nM lenalidomide. After 4 h, splenic CD4+ T cells were
isolated from MOG-treated WT mice via magnetic
separation (EasySep Mouse CD4 Isolation Kit, Stem Cell
Technologies), labeled with1 μM CFSE (Biolegend) and
subsequently cocultured with BMDMs at a ratio of 1:4 in
RPMI 1640 (GIBCO) media supplemented with
MOG35–55 peptide (20 μg/ml) for 72 h. The proliferation
of CD4+ T cells was assessed by flow cytometry based on
CFSE dilution.
Adoptive transfer of macrophages
BMDMs from WT or IL10−/− mice were cultured for
7 days and then treated with DMSO or lenalidomide
for 4 h. Cells were collected and resuspended in DMEM
without serum. In total, 3× 106 BMDMs were injected
intravenously into EAE mice at specific days depending
on the severity of disease.
Immunohistology
Spinal cords and spleen from lenalidomide- or vehicle-
treated EAE mice were embedded in OCT (SAKURA
Finetek) and spinal cords were cut into 12 μm sections
while spleen were cut into 8 μm sections. Immuno-
fluorescence staining was performed and incubated with
the appropriate dilutions of primary antibodies against
Olig2 (Millipore), CC1 (Oncogene Research), CD68, CD4,
CD8 (all purchased from Santa Cruz), IL10 (Abcam),
Arg1, p-STAT3(705) (all purchased from Cell Signaling
Technology). Subsequently, slides were incubated with
Alexa Fluor (AF) 568- or AF488-coupled secondary
antibodies (Life Technologies). Nuclei were counter-
stained with DAPI (Dojindo). For LFB staining, slides
were stained with LFB solution (Sigma-Aldrich) over-
night, rinsed with distilled water, and differentiated with
0.05% lithium carbonate solution followed by 70% etha-
nol. Differentiation was stopped by rinsing in distilled
water. For HE staining, spinal cords from lenalidomide- or
vehicle-treated EAE mice were embedded in paraffin and
cut into 3 μm sections, deparaffinized and stained with
hemotaxylin and eosin. For MBP IHC, slides were incu-
bated with the appropriate dilutions of primary antibodies
against MBP (Covance) and incubated with secondary
antibody (Beijing Zhongshan Biotechnology) for 1 h
before subjected to DAB staining. Images were taken by
Zeiss LSM510 meta fluorescence confocal microscope or
Leica DM2500 microscope.
Electron microscope
Spinal cords from lenalidomide- or vehicle-treated EAE
mice were fixed with 2.5% glutaraldehyde for 3 days. The
tissues were then PBS washed, fixed in 1% osmium tetr-
oxide for 1 h, and stained with 2% uranyl acetate for 30
min, subsequently dehydrated in graded ethanol series,
and embedded in Epon. g-ratio defined as the ratio of the
diameter of a given axon and the myelinated fiber dia-
meter. Axon and axon plus myelin units were measured
for more than 100 times for each group using ImageJ.
Western blotting and ELISA
Protein extracts were subjected to SDS-PAGE (8–12%
gels) and blotted onto PVDF membranes. After blocking
with 5% fat-free milk, the membranes were incubated
with the following antibodies: anti-AKT, anti-p-AKT,
anti-Arg-1, anti-GAPDH, anti-β-actin (all purchased from
Santa Cruz Biotechnology), anti-STAT6, anti-p-STAT6,
anti-STAT3, anti-p-STAT3(705) (all purchased from Cell
Signaling Technology), anti-Ym1, anti-IL10 (all purchased
from Abcam) at 4 °C overnight. The bound antibodies
were detected using horseradish peroxidase (HRP)-con-
jugated IgG (MULTI Sciences) and visualized with
enhanced chemiluminescence (ECL, PerkinElmer) detec-
tion reagents (Thermo scientific, USA). β-actin or
GAPDH was used as a loading control. IL-10 concentra-
tion in plasma, tissues, and cell culture supernatants were
determined by ELISA kit (DAKEWE). The tissue ELISA
measurements were normalized to the protein content of
the homogenates.
RNA isolation and qRT-PCR
Total RNA was isolated from cells with Trizol
reagent (Invitrogen), cDNA was transcribed using
TransScript kit (TransGen Biotech). qRT-PCR analysis
was performed using the SYBR Green (Bio-Rad)
method on the ABI Fast 7500 real-time PCR instrument
(Perkin-Elmer Applied Biosystems). The gene expression
was normalized to the expression of the gene encoding
GAPDH.
Monocytes isolation and flow cytometry analysis
Single-cell suspensions from spleen and draining lymph
nodes (DLN) were obtained by mechanical disruption. For
spleen cells, using NH4Cl lysis buffer to remove red blood
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cells. CNS-infiltrating monocytes were isolated from
spinal cord and brains as follows. CNS tissues were cut
into small pieces and digested in Hank’s balanced salt
solution (HBSS) containing 20mM Hepes (Sigma), 0.25%
collagenase D (GIBCO), 0.025 U/ml DNaseI (Sigma) at 37
°C for 35min with brief vortex mixing every 15 min. At
the end of digestion, the solution was mixed thoroughly
and the cells were washed twice in PBS and suspended in
30% Percoll, overlaid on 70% Percoll and centrifuged for
40min at 1300× g at 25 °C. Cells at the interface were
CNS monocytes.
Single-cell suspensions from DLN, spleen, and CNS
were incubated for 30min at 4 °C with fluorochrome-
conjugated anti-CD4, anti-CD8, anti-CD45, anti-B220 (all
purchased from BD Biosciences), anti-F4/80, anti-CD11b,
anti-CD86, and anti-CD206 (all purchased from Biole-
gend) for staining of surface markers. For intracellular
staining of cytokines, the cells were stained with anti-
CD4, followed by staining with anti-IFN-γ, anti-IL17A (all
purchased from eBioScience) and anti-IL10 (Biolegend)
using Cytofix/Cytoperm kit (BD Biosciences) according to
the manufacturer’s protocol. Intracellular staining with
anti-Foxp3 (eBioscience) was performed using an Fixa-
tion/Permeabilization kit (eBioscience) according to the
manufacturer’s protocol.
Data and statistical analysis
All data from at least three different experiments. All
values were presented as means± SEM, and statistically
significant differences were assessed by one-way ANOVA.
A value of P< 0.05 was considered statistically significant.
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